Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

392
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
392
The Placebo Effect01:54

The Placebo Effect

6.8K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.8K
Blinding01:11

Blinding

3.8K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

225
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
225
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

169
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
169
Blind Procedures02:07

Blind Procedures

12.8K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
12.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA study.

RMD open·2026
Same author

Nipocalimab for the treatment of moderate-to-severe Sjögren's disease: a plain language summary of the DAHLIAS study.

Expert review of clinical immunology·2026
Same author

Some Common Dose-Exposure-Response Estimands and Conditions for Their Causal Identifiability.

CPT: pharmacometrics & systems pharmacology·2026
Same author

An IQ Consortium Perspective on the FDA Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal Function.

Clinical pharmacology and therapeutics·2026
Same author

Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS).

Rheumatology and therapy·2025

Related Experiment Video

Updated: Jan 11, 2026

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
08:50

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

9.7K

A Model-Based Meta-Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis Trials.

Jean C Serrano1, John Maringwa2, Roel Straetemans3

  • 1Johnson & Johnson, Cambridge, Massachusetts, USA.

CPT: Pharmacometrics & Systems Pharmacology
|November 17, 2025
PubMed
Summary
This summary is machine-generated.

This study introduces a model-based meta-analysis (MBMA) for atopic dermatitis (AD) clinical trials. It reveals that concomitant therapies and baseline disease severity significantly impact placebo responses, offering insights for better trial design.

Keywords:
EASIatopic dermatitismodel‐based meta‐analysisplacebo

More Related Videos

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.6K
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.2K

Related Experiment Videos

Last Updated: Jan 11, 2026

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
08:50

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

9.7K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.6K
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.2K

Area of Science:

  • Dermatology
  • Clinical Trials
  • Biostatistics

Background:

  • Atopic dermatitis (AD) clinical trials face challenges due to high placebo response variability, complicating the evaluation of new treatments.
  • Existing meta-analyses use single time-point data, failing to capture longitudinal placebo response dynamics.

Purpose of the Study:

  • To develop and apply a model-based meta-analysis (MBMA) framework to analyze time-course projections of EASI-75 placebo responses in AD trials.
  • To identify key covariates influencing placebo response variability in moderate-to-severe AD clinical trials.

Main Methods:

  • A systematic literature review identified 40 Phase 2/3 AD trials with 4827 patients suitable for longitudinal modeling.
  • A model-based meta-analysis (MBMA) was employed to project EASI-75 placebo response over time, incorporating covariates.

Main Results:

  • Concomitant therapy, specifically topical corticosteroids (TCS), increased EASI-75 placebo rates 1.8-fold.
  • Higher baseline EASI scores were associated with lower placebo response rates (0.96-fold reduction per 1-point increase).
  • Placebo responses plateaued by Week 12, with Week 12 outcomes reflecting 94% of Week 16 projected responses.

Conclusions:

  • The MBMA framework provides a robust method for analyzing longitudinal placebo responses in AD trials.
  • Findings offer quantitative guidance for optimizing clinical trial design, power calculations, and distinguishing therapeutic effects from placebo responses in AD drug development.